Aplastic anaemia is a rare, life‐threatening disorder of the bone marrow characterised by pancytopenia and a hypocellular marrow. The primary pathophysiology involves immune-mediated destruction of ...
Eltrombopag combined with immunosuppressive therapy in pediatric patients with severe aplastic anemia achieved a 54.9% overall response rate at 26 weeks, with a 71.4% response in relapsed/refractory ...
The FDA has approved omidubicel-onlv (Omisirge, Gamida Cell Ltd.) as the first hematopoietic stem cell transplant therapy for patients with severe aplastic anemia (SAA). Specifically, omidubicel is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results